It is possible that tumor initiation in utero with these genetic alterations or in a different cell-of-origin postnatally may obviate the requirement for PDGF-A ligand (or other similar genetic alteration such as mutant PDGFRA). The gene discussed is PDGFA; the disease is neoplasm.